A clinical study app focused on on evaluating the safety and efficacy of Amcenestrant plus palbociclib as first line therapy for patients with ER(+) HER2(-) advanced breast cancer.
A clinical study app focused on on evaluating the safety and efficacy of Amcenestrant plus palbociclib as first line therapy for patients with ER(+) HER2(-) advanced breast cancer.